Institution
University of Medicine and Dentistry of New Jersey
Education•
About: University of Medicine and Dentistry of New Jersey is a based out in . It is known for research contribution in the topics: Population & Pregnancy. The organization has 14634 authors who have published 19610 publications receiving 1041794 citations.
Topics: Population, Pregnancy, Poison control, Gene, Receptor
Papers published on a yearly basis
Papers
More filters
••
Katholieke Universiteit Leuven1, Flanders Institute for Biotechnology2, Peter MacCallum Cancer Centre3, University of Melbourne4, National Institutes of Health5, International Agency for Research on Cancer6, University of Medicine and Dentistry of New Jersey7, Ghent University8, Monash University9, French Institute of Health and Medical Research10, University of California, Los Angeles11
TL;DR: It is shown that Mdm4 p53 binding protein homolog (MDM4), a negative regulator of p53, is upregulated in a substantial proportion (∼65%) of stage I–IV human melanomas and that melanocyte-specific MDM4 overexpression enhanced tumorigenesis in a mouse model of melanoma induced by the oncogene Nras.
Abstract: The inactivation of the p53 tumor suppressor pathway, which often occurs through mutations in TP53 (encoding tumor protein 53) is a common step in human cancer. However, in melanoma-a highly chemotherapy-resistant disease-TP53 mutations are rare, raising the possibility that this cancer uses alternative ways to overcome p53-mediated tumor suppression. Here we show that Mdm4 p53 binding protein homolog (MDM4), a negative regulator of p53, is upregulated in a substantial proportion (∼65%) of stage I-IV human melanomas and that melanocyte-specific Mdm4 overexpression enhanced tumorigenesis in a mouse model of melanoma induced by the oncogene Nras. MDM4 promotes the survival of human metastatic melanoma by antagonizing p53 proapoptotic function. Notably, inhibition of the MDM4-p53 interaction restored p53 function in melanoma cells, resulting in increased sensitivity to cytotoxic chemotherapy and to inhibitors of the BRAF (V600E) oncogene. Our results identify MDM4 as a key determinant of impaired p53 function in human melanoma and designate MDM4 as a promising target for antimelanoma combination therapy.
283 citations
••
TL;DR: Canakinumab provided significant pain and inflammation relief and reduced the risk of new flares in these patients with acute gouty arthritis.
Abstract: Objectives Gouty arthritis patients for whom non-steroidal anti-inflammatory drugs and colchicine are inappropriate have limited treatment options. Canakinumab, an anti-interleukin-1β monoclonal antibody, may be an option for such patients. The authors assessed the efficacy/safety of one dose of canakinumab 150 mg (n=230) or triamcinolone acetonide (TA) 40 mg (n=226) at baseline and upon a new flare in frequently flaring patients contraindicated for, intolerant of, or unresponsive to non-steroidal anti-inflammatory drugs and/or colchicine. Core study co-primary endpoints were pain intensity 72 h postdose (0–100 mm visual analogue scale and time to first new flare. Methods Two 12-week randomised, multicentre, active-controlled, double-blind, parallel-group core studies with double-blind 12-week extensions (response in acute flare and in prevention of episodes of re-flare in gout (β-RELIEVED and β-RELIEVED-II)). Results 82.6% patients had comorbidities. Mean 72-h visual analogue scale pain score was lower with canakinumab (25.0 mm vs 35.7 mm; difference, −10.7 mm; 95% CI −15.4 to −6.0; p Conclusion Canakinumab provided significant pain and inflammation relief and reduced the risk of new flares in these patients with acute gouty arthritis.
282 citations
••
TL;DR: It is concluded that tube feedings are safely tolerated by most patients; however, constant attention must be exerted to either avoid or recognize such complications.
Abstract: A review of 253 patients treated with enteral nutrition support via tube feedings is presented for the purpose of evaluating the incidence of complications. Thirty patients, (11.7%) experienced either gastrointestinal, (6.2%) mechanical (3.5%), or metabolic (2.0%) complications. The recognition and treatment of such complications are discussed and it is concluded that tube feedings are safely tolerated by most patients; however, constant attention must be exerted to either avoid or recognize such complications.
282 citations
••
TL;DR: Current understanding of the underlying mechanisms responsible for sepsis-induced cardiac dysfunction is rapidly evolving and future novel therapeutic targets may be soon available.
Abstract: Purpose of reviewSevere sepsis and septic shock are among the most important causes of morbidity and mortality in patients admitted to the intensive care unit. The purpose of this review is to review current understanding of sepsis-induced cardiac dysfunction and discuss pertinent findings regarding
282 citations
••
TL;DR: Because of the intricate involvement of several PRMT in cellular physiology, their inhibition may be fraught with unwanted side effects, Nevertheless, development of pharmaceutical agents to control PRMT functions could lead to significant new targets.
282 citations
Authors
Showing all 14639 results
Name | H-index | Papers | Citations |
---|---|---|---|
John Q. Trojanowski | 226 | 1467 | 213948 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Danny Reinberg | 145 | 342 | 68201 |
Michael F. Holick | 145 | 767 | 107937 |
Tasuku Honjo | 141 | 712 | 88428 |
Arnold J. Levine | 139 | 485 | 116005 |
Aaron T. Beck | 139 | 536 | 170816 |
Charles J. Yeo | 136 | 672 | 76424 |
Jerry W. Shay | 133 | 639 | 74774 |
Chung S. Yang | 128 | 560 | 56265 |
Paul G. Falkowski | 127 | 378 | 64898 |
Csaba Szabó | 123 | 958 | 61791 |
William C. Roberts | 122 | 1117 | 55285 |
Bryan R. Cullen | 121 | 371 | 50901 |
John R. Perfect | 119 | 573 | 52325 |